Drugs / TAK-960
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01179399 | Sep 2010 → Oct 2012 | high grade malignant neoplasm | Millennium Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-960 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01179399 ↗ |
| Action | Inhibit | “TAK-960, a Polo-Like Kinase 1 Inhibitor” NCT01179399 ↗ |
| Modality | Small molecule | — CHEMBL2392545 ↗ |
| Route | Oral | “TAK-960 administered orally once a day for 21-days of a 28-day treatment cycle” NCT01179399 ↗ |
| Target | PLK1 | “TAK-960, a Polo-Like Kinase 1 Inhibitor” NCT01179399 ↗ |